Search
Showing results for "1"
We are a collaborative group focused on improving outcomes for children with leukaemia. The Research Assistant will evaluate novel therapeutics in
Patient recruitment, sample collection & coordination of a clinical study in patients with rheumatic heart disease.
PhD Scholarship opportunities The Rio Tinto Children’s Diabetes Centre; A JDRF Global Centre of Excellence, (“the Centre”) based at The Kids Research
News & Events
CoDiab studyKayla Hesketh is the first patient recruited to a new study being carried out by the Children’s Diabetes Centre and University Children’s Hospital Basel.
The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.
Research
“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trialsEach year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.
Research
Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trialAccumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.
Research
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic LeukemiaKMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.
Research
Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphoblastic LeukemiaAcute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.
Research
Identification and genetic determination of an early life risk disposition for depressive disorder:Progress in psychiatric genetics has been slow despite evidence of high heritability for most mental disorders